Dr Habeebullah Life Sciences

To,

Date: 30/05/2018

1) BSE Limited
P.J. Towers, Dalal Street,
Mumbai – 400001

2) Metropolitan Stock Exchange of India Limited
Vibgyor Towers, 4th floor, Plot No C 62, Opp. Trident Hotel,
Bandra Kurla Complex, Bandra (E), Mumbai – 400098

3) Ahmedabad Stock Exchange Limited
Kamdhenu Complex, Opp. Sahajanand College,
Panjara Pole, Ambawadi, Ahmedabad – 380015

Dear Sir/ Madam,

Sub: Outcome of Board Meeting

Ref: Regulation 30, 33 and other applicable provisions of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 AND

Company's Letter dated 23/05/2018

Further to our above referred letter, this is to inform you that the Board of Directors of the Company at its meeting held today i.e., Wednesday, 30th May, 2018 at 3.00 PM at Registered Office, have approved and taken on record the following:

1. Audited Standalone & Consolidated Financial Results, Statement of Assets & Liabilities and Independent Auditor Reports for the Quarter IV and Year ended 31st March, 2018.

2. Approval of Standalone & Consolidated Audited Annual Accounts and Notes along with the Auditors Reports for the Financial Year 2017-18.

3. Appointment of M/s. Tungala & Co, Chartered Accountants as Internal Auditors of the Company for FY 2018-19.

4. Appointment of M/s. S.S. Reddy & Associates, Practicing Company Secretaries as Secretarial Auditors of the Company for the FY 2017-18.

In terms of second proviso to Regulation 33(3)(d) of SEBI Listing Obligations and Disclosure Requirements) Regulations, 2015; We hereby confirm and declare that the Statutory Auditors of the Company, M/s. N.M. Khatavkar & Co., Chartered Accountants have issued the Audit Reports with UNMODIFIED OPINION on the Annual Audited Financials of the Company (Standalone & Consolidated) for the Financial Year ended 31st March, 2018.

Further, as per Regulation 33(3)(b)(i) of SEBI (LODR) Regulations, 2015; the Company opts for submission of Audited Consolidated Financial Results on Yearly basis only.

DR HABEEBULLAH LIFE SCIENCES LTD.

Dr Habeebullah Life Sciences

Accordingly, please find enclosed the following:

a) Audited Standalone and Consolidated Financial Results, Statement of Assets & Liabilities of the Company for the Quarter IV and Financial Year ended 31st March, 2018.

b) Auditor's Report in respect of Audited Standalone and Consolidated Financial Results of the Company for the Quarter IV and Financial Year ended 31st March, 2018.

The meeting commenced at 3.00 PM and concluded at 5.15 PM.

Request you take the same on records.

Thanking you.

For DR HABEEBULLAH LIFE SCINCES LIMITED

K. Krishnam Raju
Executive Chairman (DIN 00874650)

DR. HABEEBULLAH LIFE SCIENCES LTD.

Encl: as above

Dr Habeebullah Life Sciences Ltd

(Formerly Known as PC Products India Limited)

Regd.Off : 2-5-36/CLRD/1, Chintalmet X Roads, Upperpally, Rajendra Nagar Mandal, Hyderabad - 500048. TS.India
Corp Off : No.11, Phase I, Vasudeva's Bloomfield Elation, Khajaguda, Nanakramguda, Hyderabad - 500008.TS. India
CIN No. : L85110TG1996PLC099198 Email : info@drhlsl.com, pcproductsindia@gmail.com
Contact No.: 040 - 2970 3333, +91 9030057370 Website : www.drhlsl.com

Dr Habeebullah Life Sciences

PART II - AUDITED STANDALONE & CONSOLIDATED STATEMENT OF PROFIT AND LOSS FOR QUARTER IV AND YEAR ENDED 31ST MARCH, 2018

(INR In Lakhs)

	Particulars	STANDALONE FINANCIALS					CONSOLIDATED FINANCIALS	
		Quarter Ended			Year Ended		Year Ended	
		3 Months Ended 31/03/2018	Preceeding 3 Months Ended 31/12/2017	Corsp. 3 months ended 31/03/2017	31-03-18	31-03-17	31-03-18	31-03-17
		Audited	Unaudited	Audited	Audited	Audited	Audited	Audited
I	Revenue from Operations	24.05	20.12	4.25	61.67	128.08	61.67	128.08
II	Other Income	-		-	-	1.35	2.81	1.35
III	Total Revenue (I+II)	24.05	20.12	4.25	61.67	129.44	64.49	129.46
IV	Expenses							
	Cost of Material Consumed	4.54	2.51	4.15	8.42	124.50	8.42	124.50
	Purchase of Stock-in-trade							
	Changes in inventories of finished goods, Work in progress and Stock in trade	-			-	-		
	Employee benefits expense	16.41	13.23	13.20	57.42	17.70	59.60	14.21
	Finance Costs							
	Depreciation and Amortisation expense	0.23			0.23		1.19	1.19
	Other Expenses	38.62	25.53	2.57	98.77	19.41	78.51	28.22
	Total Expenses	59.80	46.19	19.90	163.82	161.41	175.60	187.92
V	Profit/(Loss) from before Exceptional Items and tax (I-IV)	(35.74)	(26.07)	(15.65)	(102.15)	(31.97)	(111.12)	(58.46)
VI	Exceptional Items	-	-	-	-	-	-	-
VII	Profit/(Loss) before tax (V-VI)	(35.74)	(26.07)	(15.65)	(102.15)	(31.97)	(111.12)	(58.46)
VIII	Tax Expense:							
	(Current tax	-	-	-	-	-	-	-
	(Deferred Tax	-	-			-	(6.22)	72.29
IX	Profit/ (Loss) for the period from Continuing operations (VII-VIII)	(35.74)	(26.07)	(15.65)	(102.15)	(31.97)	(104.90)	(130.77)
X	Profit/ (Loss) from discontinuing operations	-		-	-	-	-	-
XI	Tax expense of discontinuing operations			-	-			-
XII	Profit/ (Loss) for the period from discontinuing operations after tax (X-XI)						-	-
XIII	Profit/ (Loss) for the period (IX+XII)	(35.74)	(26.07)	(15.65)	(102.15)	(31.97)	(104.90)	(130.77)
XIV	Other Comprehensive Income A) (i) Items that will not be reclassified to profit or loss (ii) Income Tax related to items that will not be reclassified to profit or loss (B) (i) Items that will be reclassified to profit or loss (ii) Income Tax relating to items that will be reclassified to profit or loss							
XV	Total Comprehensive Income for the period (XIII+XIV) (Comprising Profit (loss) and Other Comprehensive Income for the Period)	(35.74)	(26.07)	(15.65)	(102.15)	(31.97)	(104.90)	(130.77)
XVI	Comprehensive Income attributable to Non Controlling Interest						(1.34)	(47.91)
XVII	Comprehensive Income attributable to Owners of the company	(35.74)	(26.07)	(15.65)	(102.15)	(31.97)	(103.56)	(82.68)
XVIII	Earnings Per Equity Share (For Continuing Operations) (Face Value INR 10/- each)							
	1) Basic	(0.34)	(0.23)	0.15	(0.96)	(0.42)	(0.97)	(1.08)
	2) Diluted	(0.26)	(0.23)	0.15	(0.74)	(0.42)	(0.75)	(1.08)
XIX	Earnings Per Equity Share (For Discontinued Operations) (Face Value INR 10/- each) 1) Basic 2) Diluted	-	-	-	-	-	-	-
XX	Earnings Per Equity Share (For Continued and Discontinued Operations)(Face Value INR 10/- each)							
	1) Basic	(0.34)	(0.23)	0.15	(0.96)	(0.42)	(0.97)	(1.08)
	2) Diluted	(0.26)	(0.23)	0.15	(0.74)	(0.42)	(0.75)	(1.08)
XXI	Paid Up Equity Share Capital (Face Value of INR 10/- per share)	1,175.87	1,105.87	1,025.87	1,175.87	1,025.87	1,175.87	1,025.87
XXII	Reserves & Surplus (Excluding Revaluation Reserve)							

Dr Habeebullah Life Sciences

Notes:

1. In pursuance with Regulation 33 of SEBI (LODR) Regulations, 2015 and Schedule III of Companies Act, 2013, the above Financial Results have been prepared, reviewed by the Statutory Auditors of Company and recommended by Audit Committee and subsequently approved by Board of Directors of Company at their meeting held on Wednesday, 30th May, 2018.

2. The Financial Statements have been prepared in accordance with the recognition and measurement principles laid down in the Ind AS prescribed under Section 133 of Companies Act, 2013 read with the Companies (Indian Accounting Standards) Rules, 2015 (as amended).

3. The Consolidated Financial Results includes the results of the Company and its Subsidiary - Krisani Bio Sciences Private Limited.

4. The figures of the previous year/periods have been re-grouped/re-classifed, whenever necessary, for the purpose of comparison.

5. The figures of the current quarter ended 31st March, 2018 and the quarter ended 31st March, 2017 are the balancing figures between the audited figures in respect of the full financial year ended respectively and published unaudited year to date figures upto the third quarter of the respective financial years.

6. The Company has only one reportable segment i.e., **Healthcare** sector. Hence, there separate disclosure on segment information is not required.

7. As per Regulation 33(3)(b)(i) of SEBI (LODR) Regulations, 2015; the Company opts for submission of Audited Consolidated Financial Results on Yearly basis only.

8. The Audited Standalone Financials Results are summarised below:

Particulars	Quarter Ended 31-03-2018	Quarter Ended 31-12-17	Quarter Ended 31-03-17	Year Ended 31-03-18	Year Ended 31-03-17
Turnover	24.05	20.12	4.25	61.67	128.08
Profit Before Tax	(35.74)	(26.07)	(15.65)	(102.15)	(31.97)
Profit After Tax	(35.74)	(26.07)	(15.65)	(102.15)	(31.97)

9. The results are also available on the webiste of the Company www.drhlsl.com

For DR HABEEBULLAH LIFE SCIENCES LIMITED

DR HABEEBULLAH LIFE SCIENCES LTD.

Place : Hyderabad
Date :30-05-2018

K Krishnam Raju
Executive Chairman(DIN 00874650)

Dr Habeebullah Life Sciences

Statement of Assets and Liabilities

(INR. in Lakhs)

	Particulars	STANDALONE		CONSOLIDATED	
		31/03/2018	31/03/2017	31/03/2018	31/03/2017
	ASSETS				
1	**Non Current Assets**				
a	Property, Plant and Equipments	1.99	-	36.18	46.32
b	Capital Work In Progress	-	-	-	-
c	Investment Prpoerty	-	-	-	-
d	Goodwill	-	-	-	-
e	Other Intangable Assets	-	-	-	-
f	Intangable Assets under development	91.66	-	1,613.33	1,485.48
g	Biological assets other than bearer plants	-	-	-	-
h	Financial Assets:	-	-	-	-
i	Investments	487.06	487.06	0.75	0.75
ii	Trade Receivables	-	-	-	-
iii	Loans	-	-	-	-
iv	Others	235.25	30.00	195.25	30.00
v	Loans	-	-	-	-
vi	Others	-	-	-	-
i	Deferred Tax Assets (net)	-	-	36.31	30.09
j	Other Non Current Assets	-	-	-	-
	Total Non Current Asets	815.95	517.06	1,881.82	1,592.65
2	**Current Assets**				
a	Inventories	9.52	-	9.52	0.13
b	Financial Assets	-	-	-	-
i	Investments	-	-	-	-
ii	Trade Receivables	287.40	327.45	287.40	327.45
iii	Cash and Cash Equivalents	33.23	2.17	34.48	2.53
iv	Bank balances other than above	-	-	-	-
v	Loans	70.00	-	70.00	-
vi	Others	-	-	-	-
c	Current Tax Assets (net)	-	-	-	-
d	Other Current Assets	6.60	2.23	6.98	2.23
	Total Current Assets	406.76	331.86	408.39	332.35
	Total Assets	1,222.71	848.92	2,290.21	1,924.99
	EQUITY AND LIABILITIES				
1	**Equity**				
a	Equity Share Capital	1,175.87	1,025.87	1,175.87	1,025.87
b	Other Equity	-	-	-	-
i	Share Warrants	152.50	-	152.50	-
ii	Reserves and Surplus	(142.23)	(190.07)	(192.59)	(239.03)
iii	Non-Controlling Interests	-	-	414.06	415.40
	Total - Equity	1,186.15	835.80	1,549.84	1,202.24
2	**Liabilities**				
	Non Current Liabilities				
a	Financial Liabilities	-	-	-	-
i	Borrowings	-	-	-	-
ii	Trade Payables	-	-	-	-
iii	Other Financial Liabilities	-	-	-	-
b	Provisions	6.25	-	6.25	2.81
c	Deferred Tax Liabilities (net)	-	-	-	-
d	Other Non Current Liabilities	-	-	-	-
	Total Non Current Liabilities	6.25			

N. M. KHATAVKAR & CO.
CHARTERED ACCOUNTANTS

Cell : 94488 37388
Tele / Fax : 0836 2258841
Email : nandrajkhatavkar@yahoo.com
nmk1365@gmail.com

INDEPENDENT AUDITOR'S REPORT (STANDALONE)
REGULATION 33 OF SEBI (LODR) REGULATIONS, 2015

To
The Board of Directors
DR HABEEBULLAH LIFE SCIENCES LIMITED

We have audited the accompanying **Statement of Audited Standalone Financial Results ofDR HABEEBULLAH LIFE SCIENCES LIMITED (" the Company") for the Quarter IV and Year ended 31st March, 2018 ("the Statement"),**being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 05,2016.

These Standalone Quarterly Financial Results as well as the year to date financial results have been prepared on the basis of the interim financial statements, which are the responsibility of the company's management.

Our responsibility is to express an opinion on these financial results based on our audit of such interim financial statements, which have been prepared in accordance with the recognition and measurement principles laid down in Accounting Standard for Interim Financial Reporting (AS 25 / Ind AS 34), prescribed, under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. We conducted our audit in accordance with the auditing standards generally accepted in India.

We conducted our audit in accordance with the auditing standards generally accepted in India. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial results are free of material misstatement(s). An audit includes examining, on a test basis, evidence supporting the amounts disclosed as financial results. An audit also includes assessing the accounting principles used and significant estimates made by management. We believe that our audit provides a reasonable basis for our opinion.

In our opinion and to the best of our information and according to the explanations given to us these quarterly financial results as well as the year to date results:

(i) are presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 05, 2016; and

(ii) [illegible]

N. M. KHATAVKAR & CO.
CHARTERED ACCOUNTANTS

Cell : 94488 37388
Tele / Fax : 0836 2258841
Email : nandrajkhatavkar@yahoo.com
nmk1365@gmail.com

INDEPENDENT AUDITOR'S REPORT (CONSOLIDATED)
REGULATION 33 OF SEBI (LODR) REGULATIONS, 2015

To
The Board of Directors
DR HABEEBULLAH LIFE SCIENCES LIMITED

We have audited the **Statement of Audited Consolidated Financial Results of DR HABEEBULLAH LIFE SCIENCES LIMITED (" the Company") for the Quarter IV and Year ended 31st March, 2018 ("the Statement"),**being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 05, 2016.

These Consolidated Quarterly Financial Results as well as the Consolidated Year to date Financial Results have been prepared from Consolidated Interim Financial Statements, which are the responsibility of the Company's management. Our responsibility is to express an opinion on these Consolidated Financial Results based on our audit of such Consolidated Interim Financial Statements, which have been prepared in accordance with the recognition and measurement principles laid down in Accounting Standard for Interim Financial Reporting (AS 25 / Ind AS 34), mandated under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder, as applicable and other accounting principles generally accepted in India.

We conducted our audit in accordance with the auditing standards generally accepted in India. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial results are free of material misstatement(s). An audit includes examining, on a test basis, evidence supporting the amounts disclosed as financial results. An audit also includes assessing the accounting principles used and significant estimates made by

These interim financial statements and other financial informationhave been audited by other auditors whose report(s) has (have) been furnished to us, and our opinion on the quarterly financial results and the year to date results, to the extent they have been derived from such interim financialstatements is based solely on the report of such other auditors.

In our opinion and to the best of our information and according to the explanations given to us these consolidated quarterly financial results as well as the consolidated year to date results:

(i) include the YEAR TO DATE FINANCIAL RESULTS of Krisani Bio Sciences Private Limited, Hyderabad, Telangana State, India.

(ii) have been presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 05, 2016in this regard; and

(iii) give a true and fair view of the Consolidated NET LOSS and other financial information for the Quarter IV ended 31st March, 2018 (date of Quarter end)as well as the Consolidated Year to Date Results for the period from 01st April, 2017 to 31st March, 2018.

OUR OPINION ON THE STATEMENT IS UN-MODIFIED IN RESPECT OF THE ABOVE FINANCIALS WITH RESPECT TO OUR RELIANCE ON THE WORK DONE AND THE REPORTS OF OTHE AUDITORS.

Place: Hubli

For